- Revenue Growth: 25% increase in Q1 2026 driven by $137M in EPKINLY sales (+52% YoY) and $39M in Tivdak sales (+18% YoY).
- Operating Profit Expansion: 23% growth in operating profit despite $2.7B–$2.9B in operating expenses for 2026 guidance.
- Pipeline Progress: Phase III RAINFOL-02 trial for Rina-S in platinum-resistant ovarian cancer completed enrollment, with two new Phase III trials planned.
- Commercial Momentum: EPKINLY’s U.S. label removed hospitalization requirement, enhancing market adoption with $137M in Q1 sales (+52% YoY).
- Deleveraging Target: Gross leverage to fall below 3x by 2027, with Rina-S expected to launch in PROC in 2027 post-Phase III data.
Revenue Growth
Revenue climbed 25%, driven largely by the 52% YoY surge in EPKINLY and an 18% rise in Tivdak sales. The company’s guidance of 14% growth for 2026 remains intact, reflecting confidence in sustained royalty streams and expanding product pipelines.
Operating Margin
Operating margin improved to 23% despite increased pipeline and commercial investments. This margin expansion demonstrates efficient allocation of resources and the ability to scale high‑margin royalty income alongside new product launches.
Earnings per Share
EPS of $5.38 beat estimates, reflecting strong cash conversion and a low net debt/EBITDA of –0.29. The company’s free cash flow yield of 7.15% signals ample liquidity for reinvestment and shareholder returns.
EPKINLY Momentum
EPKINLY’s U.S. label change removed hospitalization requirements, fueling a 52% sales jump. The subcutaneous format and favorable safety profile are positioned to capture the frontline DLBCL market, with early-phase trials showing high CR rates and MRD negativity.
Pipeline Advances
Phase III RAINFOL‑02 for Rina‑S in platinum‑resistant ovarian cancer completed enrollment, and two new Phase III trials are slated. LiGeR studies will read out this year, while peto in CRC and colorectal programs advance, reinforcing a diversified pipeline.
Merus Integration
Merus acquisition is progressing, with integration of its portfolio expected to enhance therapeutic breadth. The integration may temporarily elevate effective tax rates, but the company projects normalization within 12–18 months, mitigating short‑term volatility.
Tax and Leverage
Effective tax rate volatility is anticipated during Merus integration; however, the firm’s deleveraging strategy targets gross leverage below 3x by 2027. The current negative net debt/EBITDA highlights a strong balance sheet foundation.
Future Catalysts
Key catalysts include 2027 Rina‑S launch in PROC, potential EPKINLY frontline DLBCL approval, and peto updates at ASCO. With a P/B of 2.84 and a robust ROE of 20.51%, Genmab is well positioned to translate clinical success into shareholder value.